Allena Pharmaceuticals develops and sells oral enzyme therapeutics to treat rare and severe metabolic disorders that affect the kidney. The company focuses on disorders that cause excess accumulation of metabolites, leading to kidney stones, damage, and potentially chronic kidney disease. Allena's proprietary approach uses non-absorbed and stable enzymes orally to reduce metabolite levels in the GI tract, reducing the disease burden on the kidney over time.